Viral and Non-Viral Vector Manufacturing Market: Current Analysis and Forecast (2022-2028 )

The viral and non-viral vector manufacturing market is expected to register a CAGR of approx. 19% over the period of 2022-2028. Viral vector manufacturing refers to the process of producing viral particles (typically viruses that have been modified) used as a delivery system for therapeutic genes. Non-viral vector manufacturing refers to the production of non-viral particles (such as nanoparticles, liposomes, or plasmids) used for gene delivery. Both methods aim to deliver therapeutic genes to target cells, but non-viral methods are generally considered safer and less immunogenic. The growing demand for viral and non-viral vector manufacturing can be attributed to the increasing government and private funding for research, and the rising demand for vector manufacturing for use in both basic and applied research are the key factors that boost the adoption of inorganic growth strategies among key industry players around the globe. For instance, In May 2022, AGC Biologics announced that it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Colo. Owing to the glaring statistics the increasing funding for research leads to higher demand for viral and non-viral vector manufacturing across the globe and would contribute to the growth of the market in the forthcoming period as well. Furthermore, the viral and non-viral vector manufacturing market is anticipated to grow on account of advancements in gene therapy. In addition, Increased demand for personalized medicine increasing demand for vector manufacturing drives the market growth. However, some of the restraints in the market including the high cost of production and strict regulatory guidelines and approval processes are impeding the growth of this market all over the world.

Based on the vector type, the viral and non-viral vector manufacturing market is segmented into a viral vector and non-viral vectors. The non-viral vectors segment accounted for a significant market share in 2021 and it is estimated that it will grow rapidly during the projected timeframe. Non-viral vectors are considered safer than viral vectors, as they do not contain live viruses and are less likely to cause immune reactions or other adverse events. they are typically easier to produce than viral vectors, which can help reduce the cost of production and can be used in a wide range of applications, including gene therapy, vaccine development, and research.

Based on the disease, the market is fragmented into cancer, genetic disease, infectious disease, cardiovascular disease, and others. The cancer segment grabbed a considerable market share in 2021, and it is expected to grow at a significant CAGR during the forecast period. An increase in the adoption of vectors for the development of cancer therapies, a large number of research programs, and recent approvals of gene therapy products led to the growth of the segment.

Based on the application, the market is fragmented into gene therapy, vaccinology, cell therapy, and others. The vaccinology segment grabbed a considerable market share in 2021, and it is expected to grow at a significant CAGR during the forecast period. Vectors can be used to develop vaccines against a wide range of pathogens, including viruses, bacteria, and parasites. The COVID-19 pandemic has increased the demand for vaccines, leading to increased interest in vector-based vaccine development.

For a better understanding of the market adoption of viral and non-viral vector manufacturing, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for the viral and non-viral vector manufacturing industry owing to the growing search and development as well as growing investment in the biotechnology sector. Moreover, the growing elderly population as well as the large patient population, including individuals with rare diseases and cancer who may benefit from vector-based therapies, increasing the demand for viral and non-viral vector manufacturing market. For instance, in 2021, According to the World Health Organization (WHO), the number of people aged 60 years and older is projected to double by 2050, with North America having a significant share of this ageing population. Owing to these glaring statistics the increase in the demand for healthcare services, including vector-based therapies is one of the major factors expanding the growth of the market. Additionally, a favourable regulatory environment for the development and commercialization of vector-based therapies well-developed healthcare infrastructure provides a favourable environment for the development and commercialization of vector-based therapies in the region.

Some of the major players operating in Boehringer Ingelheim International GmbH, Catalent Inc, FUJIFILM Holdings Corporation, Thermo Fisher Scientific Inc, Lonza Group AG, Merck KGaA, Oxford BioMedica plc, Sartorius AG, TAKARA BIO INC, and WuXi AppTec Co Ltd among others. Several M&A's along with partnerships have been undertaken.